TY - JOUR
T1 - Depression screening tools for patients with kidney failure a systematic review
AU - Kondo, Karli
AU - Antick, Jennifer R.
AU - Ayers, Chelsea K.
AU - Kansagara, Devan
AU - Chopra, Pavan
N1 - Publisher Copyright:
© 2020 by the American Society of Nephrology.
PY - 2020/12/7
Y1 - 2020/12/7
N2 - Background and objectives Patients with kidney failure experience depression at rates higher than the general population. Despite the Centers for Medicare and Medicaid Services’ ESRD Quality Incentive Program requirements for routine depression screening for patients with kidney failure, no clear guidance exists. Design, setting, participants, & measurements For this systematic review, we searched MEDLINE, PsycINFO, and other databases from inception to June 2020. Two investigators screened all abstracts and full text. We included studies assessing patients with kidney failure and compared a tool to a clinical interview or another validated tool (e.g., Beck Depression Inventory II). We abstracted data related to sensitivity and specificity, positive and negative predictive value, and the area under the curve. We evaluated the risk of bias using the Quality Assessment of Diagnostic Accuracy Studies 2. Results A total of 16 studies evaluated the performance characteristics of depression assessment tools for patients with kidney failure. The Beck Depression Inventory II was by far the best studied. A wide range of thresholds were reported. Shorter tools in the public domain such as the Patient Health Questionnaire 9 and Geriatric Depression Scale 15 (adults over 60) performed well but were not well studied. Short tools such as the Beck Depression Inventory–Fast Screen may be a good option for an initial screen. Conclusions There is limited research evaluating the diagnostic accuracy of most screening tools for depression in patients with kidney failure, and existing studies may not be generalizable to US populations. Studies suffer from limitations related to methodology quality and/or reporting. Future research should target widely used, free tools such as the Patient Health Questionnaire 2 and the Patient Health Questionnaire 9. Clinical Trial registry name and registration number: Systematic Review Registration: PROSPERO CRD42020140227.
AB - Background and objectives Patients with kidney failure experience depression at rates higher than the general population. Despite the Centers for Medicare and Medicaid Services’ ESRD Quality Incentive Program requirements for routine depression screening for patients with kidney failure, no clear guidance exists. Design, setting, participants, & measurements For this systematic review, we searched MEDLINE, PsycINFO, and other databases from inception to June 2020. Two investigators screened all abstracts and full text. We included studies assessing patients with kidney failure and compared a tool to a clinical interview or another validated tool (e.g., Beck Depression Inventory II). We abstracted data related to sensitivity and specificity, positive and negative predictive value, and the area under the curve. We evaluated the risk of bias using the Quality Assessment of Diagnostic Accuracy Studies 2. Results A total of 16 studies evaluated the performance characteristics of depression assessment tools for patients with kidney failure. The Beck Depression Inventory II was by far the best studied. A wide range of thresholds were reported. Shorter tools in the public domain such as the Patient Health Questionnaire 9 and Geriatric Depression Scale 15 (adults over 60) performed well but were not well studied. Short tools such as the Beck Depression Inventory–Fast Screen may be a good option for an initial screen. Conclusions There is limited research evaluating the diagnostic accuracy of most screening tools for depression in patients with kidney failure, and existing studies may not be generalizable to US populations. Studies suffer from limitations related to methodology quality and/or reporting. Future research should target widely used, free tools such as the Patient Health Questionnaire 2 and the Patient Health Questionnaire 9. Clinical Trial registry name and registration number: Systematic Review Registration: PROSPERO CRD42020140227.
UR - http://www.scopus.com/inward/record.url?scp=85097420373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097420373&partnerID=8YFLogxK
U2 - 10.2215/CJN.05540420
DO - 10.2215/CJN.05540420
M3 - Article
C2 - 33203736
AN - SCOPUS:85097420373
SN - 1555-9041
VL - 15
SP - 1785
EP - 1795
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 12
ER -